Stocks Health care INM
NASDAQ · Health careInMed Pharmaceuticals Inc. (INM)
It posted a net loss of $12.6M. At June 30, 2026 it held $2.2M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 9, 2026.
What InMed Pharmaceuticals Inc. does
InMed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$12.6M | -$3.12 | n/a |
| 2025 | $4.9M | -$8.2M | -$8.36 | n/a |
| 2024 | $4.6M | -$7.7M | -$20.14 | -$7M |
| 2023 | $4.1M | -$7.9M | -$64.81 | -$7.4M |
| 2022 | $1.4M | -$18.6M | -$661.43 | -$15.6M |
| 2021 | $1.9M | -$10.2M | -$756.95 | -$9.8M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What InMed Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 9, 2026
- September 9, 2026Form 425 filing 425
- September 9, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 22, 2026Form 425 filing 425
- July 22, 2026Form 425 filing 425
- July 22, 2026
- July 20, 2026Form 425 filing 425
- July 10, 2026Form 425 filing 425
Insider trades
What the people running InMed Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $161.6K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 16, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 8,340 | $10.8K |
| September 15, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 54,256 | $70.4K |
| September 14, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 28,505 | $36.9K |
| July 16, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 19 | $29.5 |
| July 16, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 2 | $3.1 |
| July 15, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 1,000 | $1.6K |
| July 15, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 13,761 | $21.3K |
| July 15, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 1,389 | $2.2K |
| July 14, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 4,882 | $7.6K |
| July 14, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 493 | $764.2 |
| July 2, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 1,460 | $2.3K |
| July 2, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 147 | $227.9 |
| July 1, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 3,946 | $6.1K |
| July 1, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 398 | $616.9 |
| June 30, 2026 | Vivo Opportunity, LLC10% owner | Boughtindirect | 545 | $839.3 |
Who owns INM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 24.1% | June 5, 2026 |
| Vivo Opportunity Fund Holdings, L.P.13D, may seek influence with 3 related filers | 21.7% | June 10, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 9.8% | May 27, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 967,120 shares in total, about $1.3M at the last price.
| Holder | Shares |
|---|---|
| ADAR1 Capital Management, LLC10% owner | 892,101892,101 held indirectly |
| Vivo Opportunity, LLC10% owner | 75,01975,019 held indirectly |
Questions about INM
What does InMed Pharmaceuticals Inc. do?
InMed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INM.
Is InMed Pharmaceuticals Inc. profitable?
No. In fiscal 2026 it reported a net loss of $12.6M.
When did InMed Pharmaceuticals Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on September 9, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from September 18, 2026.
Similar companies
Compare INM with
Follow INM
Get an email when InMed Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INM: get an email when it filesWhere the numbers come from
Financial figures are the values InMed Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.